

Docket No.: TJU0001-107
PATENT

Serial No.: 10/621,684
Filed: July 17, 2003

In the Claims:

Please amend claims 23 and 42, and add new claims 48-56 as follows.

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-22. (Canceled)

23. (Currently Amended) A pharmaceutical composition comprising:

- a) a ST receptor binding peptide ligand;
- b) a non-peptide radiostable ~~active~~ therapeutic agent; and,
- c) a pharmaceutical carrier or diluent

wherein said ST receptor binding ligand is selected from the group consisting of: a peptide, an antibody and fragments thereof.

24. (Canceled)

25. (Previously presented) The pharmaceutical composition of claim 23 wherein said ST receptor binding ligand is selected from the group consisting of: an antibody that binds to ST receptor, a peptide having an amino acid sequence SEQ ID NO:2, SEQ ID NO:3, SEQ ID NOS:5-56 and fragments and derivatives of such peptides.

26. (Previously presented) The pharmaceutical composition of claim 23 wherein said ST receptor binding ligand is a peptide having an amino acid sequence selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:54.

**Docket No.: TJU0001-107
PATENT**

**Serial No.: 10/621,684
Filed: July 17, 2003**

27. (Previously presented) The pharmaceutical composition of claim 23 wherein said ST receptor binding ligand is a peptide having an amino acid sequence of SEQ ID NO:2.

28. (Previously presented) The pharmaceutical composition of claim 23 wherein said an active agent is a therapeutic agent.

29. (Canceled)

30. (Previously presented) The pharmaceutical composition of claim 23 wherein said an active agent is selected from the group consisting of: methotrexate, doxorubicin, daunorubicin, cytosinarabioside, etoposide, 5-fluorouracil, melphalan, chlorambucil, cis-platin, vindesine, mitomycin, bleomycin, purothionin, macromomycin, and 1,4-benzoquinone derivatives.

31. (Previously presented) The pharmaceutical composition of claim 23 wherein said an active agent is 5-fluorouracil.

32. (Previously presented) The pharmaceutical composition of claim 23 wherein said ST receptor binding ligand is selected from the group consisting of: an antibody that binds to ST receptor, a peptide having an amino acid sequence SEQ ID NO:2, SEQ ID NO:3, SEQ ID NOS:5-56 and fragments and derivatives of such peptides, and the active agent is selected from the group consisting of: methotrexate, doxorubicin, daunorubicin, cytosinarabioside, etoposide, 5-fluorouracil, melphalan, chlorambucil, cis-platin, vindesine, mitomycin, bleomycin, purothionin, macromomycin, and 1,4-benzoquinone derivatives.

33. (Previously presented) The pharmaceutical composition of claim 32 wherein said ST receptor binding ligand is a peptide having an amino acid sequence selected from the group

**Docket No.: TJU0001-107
PATENT**

**Serial No.: 10/621,684
Filed: July 17, 2003**

consisting of: SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:54.

34. (Previously presented) The pharmaceutical composition of claim 32 wherein said ST receptor binding ligand is a peptide having an amino acid sequence of SEQ ID NO:2.

35. (Canceled)

36. (Previously presented) The pharmaceutical composition of claim 32 wherein said an active agent is 5-fluorouracil.

37. (Canceled)

38. (Previously presented) The pharmaceutical composition of claim 33 wherein said ST receptor binding ligand is a peptide having an amino acid sequence of SEQ ID NO:2.

39. (Previously presented) The pharmaceutical composition of claim 33 wherein said an active agent is 5-fluorouracil.

40. (Previously presented) The pharmaceutical composition of claim 39 wherein said ST receptor binding ligand is a peptide having an amino acid sequence of SEQ ID NO:2.

41. (Previously presented) The pharmaceutical composition of claim 23 wherein said pharmaceutical composition is an injectable pharmaceutical composition.

42. (Currently Amended) A pharmaceutical composition comprising:

- a) a ST receptor binding peptide ligand;
- b) a radiostable active agent; and,

Docket No.: TJU0001-107
PATENT

Serial No.: 10/621,684
Filed: July 17, 2003

c) a pharmaceutical carrier or diluent;

wherein said pharmaceutical composition is a liposome comprising a vesicle matrix wherein the ST receptor binding ligand is in the vesicle matrix and the active agent is inside the liposome, and wherein said ST receptor binding ligand is selected from the group consisting of: a peptide, an antibody and fragments thereof.

43. (Previously presented) The pharmaceutical composition of claim 42 wherein said ST receptor binding ligand is a peptide having an amino acid sequence selected from the group consisting of: an antibody that binds to ST receptor, a peptide having an amino acid sequence SEQ ID NO:2, SEQ ID NO:3, SEQ ID NOS:5-56 and fragments and derivatives of such peptides, and the active agent is selected from the group consisting of: methotrexate, doxorubicin, daunorubicin, cytosinarabioside, etoposide, 5-fluorouracil, melphalan, chlorambucil, cis-platin, vindesine, mitomycin, bleomycin, purothionin, macromomycin, 1,4-benzoquinone derivatives, trenimon, ricin, ricin A chain, Pseudomonas exotoxin, diphtheria toxin, Clostridium perfringens phospholipase C, bovine pancreatic ribonuclease, pokeweed antiviral protein, abrin, abrin A chain, cobra venom factor, gelonin, saporin, modeccin, viscumin, volkensin, alkaline phosphatase, nitroimidazole, metronidazole and misonidazole.

44. (Previously presented) The pharmaceutical composition of claim 42 wherein said ST receptor binding ligand is a peptide having an amino acid sequence of SEQ ID NO:2 said the active agent is 5-fluorouracil.

45. (Previously presented) The pharmaceutical composition of claim 42 wherein said ST receptor binding ligand is selected from the group consisting of: an antibody that binds to ST receptor, a peptide having an amino acid sequence SEQ ID NO:2, SEQ ID NO:3, SEQ ID NOS:5-56 and fragments and derivatives of such peptides.

Docket No.: TJU0001-107
PATENT

Serial No.: 10/621,684
Filed: July 17, 2003

46. (Previously presented) The pharmaceutical composition of claim 42 wherein the active agent is selected from the group consisting of: methotrexate, doxorubicin, daunorubicin, cytosinarabioside, etoposide, 5-fluorouracil, melphalan, chlorambucil, cis-platin, vindesine, mitomycin, bleomycin, purothionin, macromomycin, 1,4-benzoquinone derivatives, trenimon, ricin, ricin A chain, Pseudomonas exotoxin, diphtheria toxin, Clostridium perfringens phospholipase C, bovine pancreatic ribonuclease, pokeweed antiviral protein, abrin, abrin A chain, cobra venom factor, gelonin, saporin, modeccin, viscumin, volkensin, alkaline phosphatase, nitroimidazole, metronidazole and misonidazole.

47. (Previously presented) The pharmaceutical composition of claim 42 wherein the active agent is a non-peptide.

48. (New) A pharmaceutical composition comprising:

- a) a ST receptor binding ligand;
- b) an active agent; and,
- c) a pharmaceutical carrier or diluent;

wherein said composition is unconjugated.

49. (New) The pharmaceutical composition of claim 48 wherein said ST receptor binding ligand is selected from the group consisting of: a peptide, an antibody and fragments thereof.

50. (New) The pharmaceutical composition of claim 48 wherein said ST receptor binding ligand is selected from the group consisting of: an antibody that binds to ST receptor, a peptide having an amino acid sequence SEQ ID NO:2, SEQ ID NO:3, SEQ ID NOS:5-56 and fragments and derivatives thereof.

Docket No.: TJU0001-107
PATENT

Serial No.: 10/621,684
Filed: July 17, 2003

51. (New) The pharmaceutical composition of claim 48 wherein said ST receptor binding ligand is a peptide having an amino acid sequence selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:54.

52. (New) The pharmaceutical composition of claim 48 wherein said ST receptor binding ligand is a peptide having an amino acid sequence of SEQ ID NO:2.

53. (New) The pharmaceutical composition of claim 48 wherein said active agent is non-peptide.

54. (New) The pharmaceutical composition of claim 48 wherein said active agent is radiostable.

55. (New) The pharmaceutical composition of claim 48 wherein said active agent is a therapeutic agent.

56. (New) The pharmaceutical composition of claim 48 wherein the active agent is selected from the group consisting of: methotrexate, doxorubicin, daunorubicin, cytosinarabioside, etoposide, 5-fluorouracil, melphalan, chlorambucil, cis-platin, vindesine, mitomycin, bleomycin, purothionin, macromomycin, 1,4-benzoquinone derivatives, trenimon, ricin, ricin A chain, Pseudomonas exotoxin, diphtheria toxin, Clostridium perfringens phospholipase C, bovine pancreatic ribonuclease, pokeweed antiviral protein, abrin, abrin A chain, cobra venom factor, gelonin, saporin, modeccin, viscumin, volkensin, alkaline phosphatase, nitroimidazole, metronidazole and misonidazole.